Actively Recruiting
Study of Alcarisa Hyaluronic Acid Filler for Safe and Effective Mid-face Volume Restoration in Adults Aged 30 to 65
Led by Espad Pharmed · Updated on 2025-09-02
30
Participants Needed
2
Research Sites
26 weeks
Total Duration
AI-Summary
What This Trial Is About
Researchers are evaluating the safety and effectiveness of a hyaluronic acid filler called Alcarisa, produced by Espad Pharmed Co., for treating mid-face volume loss, a condition that can affect appearance and self-confidence. This single-arm, before-and-after clinical study focuses on adults aged 30 to 65 with moderate to significant mid-face volume loss. The purpose is to assess improvements in facial volume and participant satisfaction after treatment. The study involves a one-time injection of 2 to 4 cc of Alcarisa gel into the zygomaticomalar area, and if the physician finds it appropriate, also into the anteromedial cheek and submalar areas on both sides of the face. The treatment is delivered in a single session, with no additional interventions planned. The effects and safety of the filler will be monitored over a 24-week period after injection. Participants will have digital photos taken before the injection, immediately after, and at 4, 12, and 24 weeks post-treatment to help the physician evaluate changes in mid-face volume and safety. Participant satisfaction will also be assessed at these intervals. The primary outcome is a reduction in mid-face volume deficit at 4 weeks, with further measurements taken up to 24 weeks. Safety assessments include monitoring for adverse events throughout the study period.
CONDITIONS
Brief Title
Evaluation of Efficacy and Safety of Alcarisa (Hyaluronic Acid Produced by Espad Pharmed Co.) for Restoration of Mid-face Volume
Not the Right Trial for You?
Explore thousands of other clinical trials that might be a better match.
Sign up to get personalized trial recommendations delivered to your inbox.
Already have an account? Log in here